Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT04604197
Active, not recruiting Not applicable

ANGiographic Evaluation of Left Main Coronary Artery INtErvention

NCT04604197 · tracked via the Priya Life Science Spain tracker
Sponsor
Fundación EPIC
Phase
Not applicable
Started
2021-04-16
Last updated
2026-02-13

Condition(s) studied

Coronary OcclusionLeft Main Coronary Artery DiseaseCoronary Artery StenosisCoronary DiseaseCoronary Artery Disease

Investigational drug(s) / intervention(s)

Angiography and Clinical Follow upClinical Follow up

Angiography and Clinical Follow up: Angiography and Clinical Follow up

Clinical Follow up: Clinical Follow up

Study summary

To assess if an angiographic follow-up at 6 months after Percutaneous Coronary Intervention in Left Main Coronary Artery Disease decrease the composite objective of death, myocardial infarction, and stroke at 36 months.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
No
Inclusion Criteria: * Age: 18- 85 years at the date of the PCI. * With PCI for presenting de novo lesions in the Left Main Artery by implanting a cobalt-chrome stent with everolimus-eluting fluoropolymer. * Informed consent signed. Exclusion Criteria: * Refusal to participate in the study. * Patients with left main disease who have been admitted with STEMI and have undergone primary angioplasty in a culprit lesion different than the left main. The left main lesion has been treated as a stage procedure and discharged with left ventricular ejection fraction \< 35 %. * Previous coronary surgery. * Creatinine clearance \<40 ml / min. * Contraindication for double antiaggregation after PCI. * Patients life expectancy \<36 months. * Included in other studies or clinical trials. * Pregnant or lactating women.

Primary outcome measure(s)

Trial sites (30)

FacilityCityRegionStatus
Hospital Universitari Germans Trias I Pujol Badalona Barcelona
Hospital Universitario de Cruces Barakaldo Bizkaia
Hospital Universitario Donostia Donostia / San Sebastian Gipuzkoa
Hospital Universitario Regional de Malaga Málaga Malaga
Hospital Galdakao-Usansolo Galdakao Vizcaya
Hospital Universitario de A Coruña A Coruña Spain
Hospital General Universitario de Albacete Albacete Spain
Hospital General Universitario de Alicante Alicante Spain
Hospital Universitario San Juan de Alicante Alicante Spain
Hospital Del Mar Barcelona Spain
Hospital Universitari Vall D'Hebron Barcelona Spain
Hospital Universitari Bellvitge Barcelona Spain
Hospital Universitario de Ciudad Real Ciudad Real Spain
Hospital Universitario Reina Sofia Córdoba Spain
Hospital Universitario de Cabueñes Gijón Spain
Hospital Universitario Virgen de Las Nieves Granada Spain
Hospital General Juan Ramón Jiménez Huelva Spain
Hospital Universitario de León León Spain
Hospital Universitario Lucus Agusti Lugo Spain
Hospital Universitario La Princesa Madrid Spain
Hospital Universitario Ramon Y Cajal Madrid Spain
Hospital Universitario 12 de Octubre Madrid Spain
Hospital Universitario La Paz Madrid Spain
Hospital Universitario Virgen Arrixaca Murcia Spain
Hospital Universitario Marques de Valdecilla Santander Spain
Hospital Clínico Universitario de Santiago de Compostela Santiago de Compostela Spain
Hospital Clinico Universitario de Valencia Valencia Spain
Hospital Clinico Universitario de Valladolid Valladolid Spain
Hospital Clinico Universitario Lozano Blesa Zaragoza Spain
Hospital Universitario Miguel Servet Zaragoza Spain

More Fundación EPIC trials in Spain

Parenteral Antiplatelet Agents in Real-world Spanish PCI Patients Active, not recruiting
Comparison Between Optical Coherence Tomography and Intravascular Ultrasound for Intermediate Left Main Coronary Artery Lesions Active, not recruiting
Cross-over Study of Coronary Risk Factors With a Polypill Recruiting
PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients Active, not recruiting
Sequent Extended Study Active, not recruiting

Other trials for the same condition

First in Men Study: BIOMAG-I Active, not recruiting
Comparison Between Optical Coherence Tomography and Intravascular Ultrasound for Intermediate Left Main Coronary Artery Lesions Active, not recruiting
Cross-over Study of Coronary Risk Factors With a Polypill Recruiting
PREVAIL Paclitaxel-coated Balloon in Small Coronary Disease and High-bleeding Risk Patients Active, not recruiting
Sequent Extended Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04604197 on ClinicalTrials.gov ↗ ← All trials in Spain